Linkedin Facebook Contact with Pharma Industrial India
 

Last edition

March-April, 2026
All magazines
Subscribe to our magazine
autodoc
 
Home › News › Global Pharma

Venus Remedies Achieves Marketing Authorizations for Docetaxel in Israel and Cytarabine in Colombia

Venus Remedies Achieves Marketing Authorizations for Docetaxel in Israel and Cytarabine in Colombia

Venus Remedies announce dual achievements in securing marketing authorisations for three variants of Docetaxel in Israel and Cytarabjne 100MG in Colombia.

The approved Docetaxel variants (160MG/8ML, 80MG/4ML, 20MG/1ML) and Cytarabine further solidify our commitment to advancing healthcare solutions globally.
Read more on:
More news about: global pharma | Published by Manvi | December - 22 - 2023 | 631

Last news about this category

Onco-Innovations Subsidiary Partners with GSK on Real-World Oncology Data Research Onco-Innovations Subsidiary Partners with GSK on Real-World Oncology Data Research
Cellenkos Receives US FDA IND Clearance for CK0802 Phase 1b/ 2a Trial in GVHD Cellenkos Receives US FDA IND Clearance for CK0802 Phase 1b/ 2a Trial in GVHD
Incyte Wins US FDA Approval for Jakafi XR (Ruxolitinib) Incyte Wins US FDA Approval for Jakafi XR (Ruxolitinib)
Arrowhead Pharmaceuticals Wins Australia TGA Approval for REDEMPLO Arrowhead Pharmaceuticals Wins Australia TGA Approval for REDEMPLO
China's Center of Drug Evaluation Accepts Marketing Authorisation Application for Bayer's FXIa Inhibitor China's Center of Drug Evaluation Accepts Marketing Authorisation Application for Bayer's FXIa Inhibitor
Pfizer Reaches Three Settlement Deals for VYNDAMAX Pfizer Reaches Three Settlement Deals for VYNDAMAX
US FDA Approves Regeneron's Otarmeni, First Gene Therapy for Genetic Hearing Loss US FDA Approves Regeneron's Otarmeni, First Gene Therapy for Genetic Hearing Loss
AbbVie Provides US Regulatory Update on TrenibotE BLA AbbVie Provides US Regulatory Update on TrenibotE BLA
Integrated DNA Technologies Expands Manufacturing Capacity to Boost Cancer Research Solutions Integrated DNA Technologies Expands Manufacturing Capacity to Boost Cancer Research Solutions
Syntegon Posts Record Year in 2025 and Aims for Further Growth Syntegon Posts Record Year in 2025 and Aims for Further Growth
 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members

Privacy Policy | Cookies Policy